Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Pathologic Complete Response 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

aldesleukin 22Sunitinib 21Bevacizumab 16Interleukin-2 14Everolimus 14Interferon-alpha 13Gemcitabine 13Cyclophosphamide 13fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 9Sorafenib 8Filgrastim 8Axitinib 8Nivolumab 7pembrolizumab 6Ipilimumab 6Doxorubicin 6Carboplatin 6sargramostim 5cabozantinib 5Capecitabine 5Thalidomide 4Tacrolimus 4Radiotherapy 4Radiosurgery 4Neoadjuvant Therapy 4Mycophenolic Acid 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Neoplasms × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT00085436 2018-06-26

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡